Aaron Bloomer
CFO at Exact Sciences
We are raising total revenue guidance to between 3,130,000,000.00 and $3,170,000,000 for the year, an increase of $55,000,000 at midpoint, with third quarter revenue between 800,000,000 and $815,000,000 This assumes screening revenue between $630,000,000 and $640,000,000 for the third quarter and between 2,440,000,000.00 and $2,470,000,000 for the year Precision Oncology revenue between $170,000,000 and $175,000,000 for the third quarter and between $690,000,000 and $700,000,000 for the year Annual guidance at midpoint implies total revenue growth of 14% including 17% in screening and 6% in precision oncology. We are raising full year adjusted EBITDA guidance by $25,000,000 to between $455,000,000 to $475,000,000 for the full year. Guidance at midpoint implies more than 44% adjusted EBITDA growth or about 300 basis points of adjusted EBITDA margin expansion. For modeling purposes, please note our adjusted EBITDA guidance does not reflect any potential impact from the Fresenome licensing agreement announced today. We will provide updated guidance upon the close of the transaction.